A retrospective, non-randomized, clinical review on the effect of single-dose biosimilar Razumab injection in diabetic macular edema

Arul Balasubramanian; Jeyaprakash Balasubramanian; Atchaya Pugazhenthi; Chandru Balasivaraman; Divya Murugadass; Kothai Ramalingam

doi:10.52756/ijerr.2023.v32.010

Authors

Arul Balasubramanian Department of Pharmacy Practice, Vinayaka Mission’s College of Pharmacy, Vinayaka Mission’s Research Foundation, (Deemed to be University), Salem, Tamilnadu, India https://orcid.org/0000-0001-6896-5069
Jeyaprakash Balasubramanian Department of Ophthalmology, Vinayaka Mission’s Kirupananda Variyar Medical College & Hospitals, Vinayaka Mission’s Research Foundation, (Deemed to be University), Salem, Tamilnadu, India https://orcid.org/0000-0001-7814-650X
Atchaya Pugazhenthi Department of Pharmacy Practice, Vinayaka Mission’s College of Pharmacy, Vinayaka Mission’s Research Foundation, (Deemed to be University), Salem, Tamilnadu, India https://orcid.org/0009-0007-2067-3877
Chandru Balasivaraman Department of Pharmacy Practice, Vinayaka Mission’s College of Pharmacy, Vinayaka Mission’s Research Foundation, (Deemed to be University), Salem, Tamilnadu, India https://orcid.org/0009-0007-6265-3014
Divya Murugadass Department of Pharmacy Practice, Vinayaka Mission’s College of Pharmacy, Vinayaka Mission’s Research Foundation, (Deemed to be University), Salem, Tamilnadu, India https://orcid.org/0009-0007-2067-3877
Kothai Ramalingam Department of Pharmacy Practice, Vinayaka Mission’s College of Pharmacy, Vinayaka Mission’s Research Foundation, (Deemed to be University), Salem, Tamilnadu, India https://orcid.org/0000-0002-4571-0917

DOI:

https://doi.org/10.52756/ijerr.2023.v32.010

Keywords:

Biosimilar Razumab, Diabetic macular edema, Macular thickness, Visual acuity

Abstract

Diabetic macular edema (DME) is one of the microvascular complications of diabetes and also coexists with diabetic retinopathy. The present study aims to investigate the effectiveness of single-dose biosimilar Razumab injection in diabetic macular edema. In this retrospective, non-randomized, clinical review on patients (n=50), 50 eyes with diabetic macular edema were selected and treated with a single dose of 2.3mg/0.23mL Razumab injection intravitreally. Visual acuity (VA) and macular thickness (MT), were evaluated for a period of up to 45 days after injecting biosimilar Razumab and were used to assess the effectiveness after treatment for 45 days. The results of the study showed that there was a significant increase in visual acuity and a marked reduction in macular thickness and the intraocular pressure (IOP) and anterior segment (AS) examination reverted to normal after the injection (Day 45). This study concludes that a single dose of biosimilar Razumab injection was effective in improving visual acuity and reducing macular thickness with no ocular concerns in diabetic macular edema patients.

References

Browning, D. J., Stewart, M. W., & Lee, C. (2018). Diabetic macular edema: Evidence-based management. Indian Journal of Ophthalmology, 66(12), 1736–1750. https://doi.org/10.4103/ijo.IJO_1240_18

Buabbud, J. C., Al-latayfeh, M. M., & Sun, J. K. (2010). Optical coherence tomography imaging for diabetic retinopathy and macular edema. Current Diabetes Reports, 10(4), 264–269. https://doi.org/10.1007/s11892-010-0129-z

Campochiaro, P. A., Heier, J. S., Feiner, L., Gray, S., Saroj, N., Rundle, A. C., Murahashi, W. Y., & Rubio, R. G. (2010). Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology, 117(6), 1102-1112.e1. https://doi.org/10.1016/j.ophtha.2010.02.021

Chen, N.N., Chen, W.D., Lai, C.H., Kuo, C.N., Chen, C.L., Huang, J.C., Wu, P.C., Wu, P.L., & Chen, C.Y. (2020). Optical Coherence Tomographic Patterns as Predictors of Structural Outcome After Intravitreal Ranibizumab in Diabetic Macula Edema. Clinical Ophthalmology (Auckland, N.Z.), 14, 4023–4030. https://doi.org/10.2147/OPTH.S264669

Ferrara, N., Damico, L., Shams, N., Lowman, H., & Kim, R. (2006). Development of ranibizumab, an anti–vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina,26(8), 859–870. https://doi.org/10.1097/01.iae.0000242842.14624.e7

Giridhar, S., Verma, L., Rajendran, A., Bhende, M., Goyal, M., Ramasamy, K., Rajalakshmi, Padmaja, R., Natarajan, S., Palanivelu, M. S., Raman, R., & Sivaprasad, S. (2021). Diabetic macular edema treatment guidelines in India: All India Ophthalmological Society Diabetic Retinopathy Task Force and Vitreoretinal Society of India consensus statement. Indian Journal of Ophthalmology, 69(11), 3076–3086. https://doi.org/10.4103/ijo.IJO_1469_21

Gopal, S., Kasturirangan, S., Madhivanan, N., Henry, H., Nivean, P., & Shekharan, S. (2020). Clinical effectiveness and safety of razumab (a biosimilar of ranibizumab). TNOA Journal of Ophthalmic Science and Research, 58(3), 154. https://doi.org/10.4103/tjosr.tjosr_41_20

Itoh, Y., Petkovsek, D., Kaiser, P. K., Singh, R. P., & Ehlers, J. P. (2016). Optical Coherence Tomography Features in Diabetic Macular Edema and the Impact on Anti-VEGF Response. Ophthalmic Surgery, Lasers and Imaging Retina, 47(10), 908–913. https://doi.org/10.3928/23258160-20161004-03

Kartasasmita, A., Elvioza, E., & Muhiddin, H. S. (2018). Ranibizumab in Diabetic Macular Edema; Level 1 and Level 2 Studies Findings. Ophthalmology Journal, 3(1), 14–20. https://doi.org/10.5603/OJ.2018.0028

Lee, R., Wong, T. Y., & Sabanayagam, C. (2015). Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and Vision, 2(1), 1–25. https://doi.org/10.1186/s40662-015-0026-2

Massin, P., Bandello, F., Garweg, J. G., Hansen, L. L., Harding, S. P., Larsen, M., Mitchell, P., Sharp, D., Wolf-Schnurrbusch, U. E. K., Gekkieva, M., Weichselberger, A., & Wolf, S. (2010). Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care, 33(11), 2399–2405. https://doi.org/10.2337/dc10-0493

Mathew, C., Yunirakasiwi, A., & Sanjay, S. (2015). Updates in the management of diabetic macular edema. Journal of Diabetes Research, 2015, 794036. https://doi.org/10.1155/2015/794036

Minami, Y., Nagaoka, T., Ishibazawa, A., & Yoshida, A. (2016). Short-term effect of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion. Retina (Philadelphia, Pa.), 36(9), 1726–1732. https://doi.org/10.1097/IAE.0000000000000991

Nguyen, Q. D., Shah, S. M., Khwaja, A. A., Channa, R., Hatef, E., Do, D. V., Boyer, D., Heier, J. S., Abraham, P., Thach, A. B., Lit, E. S., Foster, B. S., Kruger, E., Dugel, P., Chang, T., Das, A., Ciulla, T. A., Pollack, J. S., Lim, J. I., … Campochiaro, P. A. (2010). Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology, 117(11), 2146–2151. https://doi.org/10.1016/j.ophtha.2010.08.016

Otani, T., Kishi, S., & Maruyama, Y. (1999). Patterns of diabetic macular edema with optical coherence tomography. American Journal of Ophthalmology, 127(6), 688–693. https://doi.org/10.1016/s0002-9394(99)00033-1

Pożarowska, D., & Pożarowski, P. (2016). The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Central-European Journal of Immunology, 41(3), 311–316. https://doi.org/10.5114/ceji.2016.63132

Preethi, B., Shilpa, G., Shah, D. A., & Murthy, P. R. (2021). A comparative study between ranibizumab and its first biosimilar razumab in terms of efficacy and safety in DME, RVO and wet AMD associated with CNVM. Indian Journal of Clinical and Experimental Ophthalmology, 7(2), 346–351. https://doi.org/10.18231/j.ijceo.2021.068

Radovanova, K. T. (2014). Optical Coherence Tomography Patterns in Diabetic Macular Edema can Predict the Effectiveness of Intravitreal Bevacizumab Combined with Macular Photocoagulation. Journal of Clinical & Experimental Ophthalmology, 05(05). https://doi.org/10.4172/2155-9570.1000355

Raman, R., Vasconcelos, J. C., Rajalakshmi, R., Prevost, A. T., Ramasamy, K., Mohan, V., Mohan, D., Rani, P. K., Conroy, D., Das, T., Sivaprasad, S., Bhende, P., Surya, J., Gopal, L., Ramakrishnan, R., Roy, R., Das, S., Manayath, G., Pooleeswaran, V. T., … Kulkarni, S. (2022). Prevalence of diabetic retinopathy in India stratified by known and undiagnosed diabetes, urban–rural locations, and socioeconomic indices: results from the SMART India population-based cross-sectional screening study. The Lancet Global Health, 10(12), e1764–e1773. https://doi.org/10.1016/S2214-109X(22)00411-9

Ratra, D., Roy, K., Giridhar, S., Madaan, S., Bhende, P., Bhende, M., Rao, G., Sen, P., Raman, R., Khetan, V., Rao, C., Pradeep, S., Muralidharan, V., Suganeswari, G., Roy, R., Das, D., Mukherjee, S., Rajesh, P. S., Jayaprakash, V., … Das, K. (2022). Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation. Ophthalmology and Therapy, 11(1), 135–149. https://doi.org/10.1007/s40123-021-00416-4

Romero-Aroca, P., Baget-Bernaldiz, M., Pareja-Rios, A., Lopez-Galvez, M., Navarro-Gil, R., & Verges, R. (2016). Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. Journal of Diabetes Research, 2016, 2156273. https://doi.org/10.1155/2016/2156273

Sameera, V., Apoorva, A., Joshi, S., & Guruprasad, A. (2016). Safety and efficacy of Razumab – The new biosimilar in India: Our experience. Kerala Journal of Ophthalmology, 28(3), 180. https://doi.org/10.4103/kjo.kjo_18_17

Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017). Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. Journal International d’ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 237(4), 185–222. https://doi.org/10.1159/000458539

Scholl, S., Kirchhof, J., & Augustin, A. J. (2010). Pathophysiology of Macular Edema. Ophthalmologica, 224(Suppl. 1), 8–15. https://doi.org/10.1159/000315155

Seo, K. H., Yu, S.-Y., Kim, M., & Kwak, H. W. (2016). Visual and Morphologic Outcomes of Intravitreal Ranibizumab for Dabetic macular edema based on Opticl coherence tomography patterns. Retina (Philadelphia, Pa.), 36(3), 588–595. https://doi.org/10.1097/IAE.0000000000000770

Sharaf, A., Nabawi, K., Shalaby, T., & Swelem, H. (2015b). Short-term results of intravitreal ranibizumab injection in eyes with diabetic macular edema. Delta Journal of Ophthalmology, 16(2), 77. https://doi.org/10.4103/1110-9173.168536

Suñer, I. J., Bressler, N. M., Varma, R., Lee, P., Dolan, C. M., Ward, J., Colman, S., & Rubio, R. G. (2013). Reading Speed Improvements in Retinal Vein Occlusion After Ranibizumab Treatment. JAMA Ophthalmology, 131(7), 851. https://doi.org/10.1001/jamaophthalmol.2013.114

Vashist, P., Senjam, S. S., Gupta, V., Gupta, N., Shamanna, B. R., Wadhwani, M., Shukla, P., Manna, S., Yadav, S., & Bharadwaj, A. (2022). Blindness and visual impairment and their causes in India: Results of a nationally representative survey. PLoS ONE, 17(7 July), 1–14. https://doi.org/10.1371/journal.pone.0271736

Verma, L., Thulasidas, M., Purohit, A., Gupta, A., Narula, R., & Talwar, D. (2021). Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world’s first biosimilar Ranibizumab. Indian Journal of Ophthalmology, 69(2), 347–351. https://doi.org/10.4103/ijo.IJO_2516_20

Yumusak, E., Kücükevcilioglu, M., Ornek, K., & Büyüktortop, N. (2016). Effect of a Single Intravitreal Ranibizumab Injection on Diabetic Macular Edema in Patients Who Discontinued Treatment. Journal of Clinical and Experimental Investigations, 7(2). https://doi.org/10.5799/ahinjs.01.2016.02.0595